ArticleMedical mycology2025
The in vitro activity of iron chelator deferiprone against Candida (Candidozyma) auris in combination with antifungal agents.
Article in Medical mycology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathogenicity and virulence ofVirulence · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Candida (Candidozyma) auris is well known for its limited susceptibility to conventional antifungal agents, underscoring the need for novel alternative therapeutic approaches. One such approach, which involves restricting the availability of micronutrients-including iron-is a promising antimicrobial strategy and proven to enhance the efficacy of various antimicrobial agents in vitro. In this study, we evaluated the activity of deferiprone, a clinically approved iron-chelating agent, in combination with echinocandins, amphotericin B and fluconazole against C. auris strains, including three echinocandin-resistant isolates representing the four major clades. Drug-drug interactions were assessed using the chequerboard methodology. Fractional inhibitory concentration index scores ranged from 0.5 to 2.25 and 0.1875 to 4.125 for anidulafungin; 0.375 to 1.5 and 0.125 to 1.5 for micafungin; 0.3125 to 1.5 and 0.3125 to 2 for caspofungin; 0.375 to 2.0625 and 0.375 to 2 for amphotericin B; and 0.625 to 2 and 0.625 to 2 for fluconazole at 24 and 48 h, respectively. Synergistic interactions were most frequently observed with echinocandins, while interactions with fluconazole and amphotericin B were generally additive or indifferent, except in Clade II. Antagonism was observed in only one instance. These findings suggest that iron chelation may potentiate the antifungal activity of echinocandins against C. auris in a clade- and isolate-specific manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.